Chemed Corporation

[CHE] Chemed Thesis 2026: A VITAS Hospice Engine and Roto-Rooter Plumbing Franchise Compound Quietly

Chemed Corporation (NYSE: CHE) is a Cincinnati, Ohio-headquartered two-business holding company that owns and operates two leading US service businesses: VITAS Healthcare (the largest for-profit hospice provider in the United States) and Roto-Rooter (the largest plumbing, drain-cleaning and water-restoration provider). The corporate history traces back to a 1970s diversified conglomerate (Chemed was at one point part of W.R. Grace, then an independent specialty-chemicals company, then divested its chemicals businesses to focus on the two services franchises); Chemed acquired Roto-Rooter (originally founded 1935) over decades, and acquired the hospice operator that became VITAS (founded 1978 as one of the original US hospice providers) and built it through bolt-ons. The company is run with a deliberately decentralized, low-corporate-overhead style — the two operating businesses operate largely independently with their own management teams, and corporate Chemed focuses on capital allocation, governance and consolidated reporting. Longtime President & CEO Kevin J. McNamara has run Chemed for a multi-decade tenure. The two businesses are very different — VITAS is healthcare-services (Medicare-reimbursed, regulated, labor-intensive) and Roto-Rooter is consumer/commercial trade services (cyclical, weather-sensitive, demand-driven) — but they share defensive characteristics, strong FCF conversion, and dominant US market positions. Geography is overwhelmingly US. The capital structure is conservative — modest debt, often net-cash, no large M&A swings, with cash flow directed at dividends + heavy buybacks + selective bolt-ons. CHE enters FY2026 with FY2025 revenue selected various aggregate ~$2.35-2.65B (~mid-single-digit % growth), aggregate adjusted EPS ~$22-26 and adjusted EBITDA ~$390-450M (~16-18% margin). The first thesis pillar is VITAS Healthcare — the larger and higher-quality of the two businesses (~half-plus of revenue, higher-margin than Roto-Rooter): the business delivers hospice care — interdisciplinary palliative care for terminally ill patients with a prognosis of six months or less — through a clinical team (nurses, physicians, social workers, chaplains, hospice aides, volunteers) that visits patients in homes, nursing facilities, assisted-living, hospitals or VITAS inpatient units; VITAS operates in ~14 states (CA, FL, TX, IL, PA, NJ — dense-population states) with ~18-22 thousand patients/day average daily census; revenue ~90%+ from Medicare hospice fee-for-service per-diem (varying by level of care — routine home care the bulk, plus continuous home care, GIP, respite — updated annually by CMS via the Medicare hospice payment update, typically low-single-digit %); the hospice cap is a key compliance metric (Medicare imposes a per-beneficiary aggregate-payment cap; exceeding requires a refund — VITAS manages census mix and length of stay to stay within); the competitive landscape: VITAS the largest for-profit, competing with Amedisys (AMED, pending UnitedHealth merger), Encompass Health (EHC), Addus HomeCare (ADUS), Aveanna (AVAH), UnitedHealth's (UNH) Optum/LHC, plus not-for-profits and a fragmented small/regional landscape; FY2025 dynamics are admissions and average daily census growing (post-pandemic recovery + aging-population demographics + late-stage cancer/dementia/COPD admissions), length-of-stay watched, nursing-labor cost/availability pressures, revenue growing mid-single-digit, margin holding/expanding modestly; FY2026 catalyst is admissions and census growth, the Medicare payment update, the hospice cap, nursing-labor dynamics, mix shifts, and selective tuck-in M&A; risks/competitors are Medicare reimbursement changes (rates, the cap, regulatory scrutiny, audits — hospice has had episodic government attention with periodic enforcement actions and false-claims cases industry-wide), nursing-labor shortages, length-of-stay/census volatility, and the broader for-profit-hospice competitive set. The second pillar is Roto-Rooter — the smaller, more cyclical, but franchise-strong business (~the remaining portion of revenue): Roto-Rooter is the leading US brand in plumbing services, drain-cleaning, sewer-cleaning and water-restoration — services to residential and commercial customers 24/7, dispatched by call or online booking, with technicians in branded service vehicles; the model combines company-owned branches (the bulk of Chemed's Roto-Rooter revenue) with a franchise network (royalties — the smaller, high-margin piece); services span drain cleaning (the original 1935 product), plumbing repairs (leaks, fixtures, water heaters, sewer lines), water-damage restoration (drying, dehumidification, water extraction, mold remediation — winter freezes, heavy rain/flooding, hurricane events drive demand spikes), and sewer/septic; the brand is extraordinarily strong ('Roto-Rooter' is generic in many consumer minds for drain cleaning), with substantial digital lead-generation (SEO, paid search, Yelp, online booking, branded apps) plus branded fleet vehicles; FY2025 dynamics are residential plumbing mixed (housing-turnover-sensitive softer, water-restoration steady-to-strong on weather, drain-cleaning steady), pricing modestly higher, technician labor a watch item, digital lead-acquisition costs rising; FY2026 catalyst is residential plumbing demand, water-restoration call volumes (weather-event driven), pricing/mix, technician availability and productivity, digital lead generation, and any franchise/branch acquisition; risks/competitors are housing-turnover cyclicality (recessions reduce discretionary repairs), weather-event variability, intense local competition from ARS/Rescue Rooter, Mr. Rooter (Neighborly), Benjamin Franklin Plumbing, local plumbing contractors, HVAC-and-plumbing private-equity roll-ups (Frontier Service Partners, Comfort Systems USA (FIX) on the larger commercial side, ServiceMaster's home-services brands), technician-labor inflation, and digital lead-cost inflation. The capital story: a growing dividend (~$1.80-2.05/share annually, ~0.3-0.5% yield — modest yield by design, with focus on growth; many consecutive years of raises), heavy share buybacks (~14-16M diluted shares — a small float — fallen meaningfully over decades through a multi-billion-cumulative repurchase program), net debt ~$0-300M (often net-cash between deals/buyback batches, well below 1x net debt/EBITDA, often net cash), investment-grade or IG-equivalent credit, capital allocation working capital/capex (modest — service businesses) → grow dividend → aggressive buybacks → selective bolt-on M&A (hospice agencies for VITAS, plumbing/water-restoration tuck-ins for Roto-Rooter) → near-net-cash balance, with the steady FCF generation, buyback pace vs cash balance, bolt-on M&A pricing discipline, and the long capital-return track record supporting a premium services-sector multiple as the principal considerations. At ~$450-650 per share on ~14-16M shares (~$7-10B equity, EV broadly similar given near-net-cash) CHE trades at roughly ~20-28x P/E, ~16-22x EV/EBITDA and ~22-30x EV/FCF with a ~0.3-0.5% dividend yield — a premium-services multiple rewarding defensive end-markets, dominant market positions, strong FCF conversion, conservative balance sheet, and multi-decade compounding via buybacks — versus mixed comps: hospice/home-health Amedisys (AMED, pending UnitedHealth), Encompass Health (EHC), Addus HomeCare (ADUS), Aveanna Healthcare (AVAH), UnitedHealth's (UNH) Optum/LHC; plumbing/services Comfort Systems USA (FIX), API Group (APG), Rollins (ROL, branded-services consumer comp), Cintas (CTAS); diversified services compounders Roper (ROP), Heico (HEI). FY2026 base case: ~$2.5-2.8B revenue + ~$23-28 adj. EPS + ~$410-470M adjusted EBITDA + VITAS census growing + Roto-Rooter steady + growing dividend + aggressive buybacks + bolt-on M&A — solid compounding; bull case: ~$2.6-2.95B+ revenue + ~$26-32+ adj. EPS on a stronger VITAS census ramp (favorable demographics + admission improvements + hospice cap managed well), a favorable Medicare payment update, Roto-Rooter benefiting from a busy weather year (water-restoration surge) and housing-turnover recovery, accretive bolt-on M&A, continued buybacks, and a re-rating; bear case: ~$2.2-2.4B revenue + ~$19-23 adj. EPS on a Medicare reimbursement/regulatory headwind (hospice cap tightening, payment-update freeze, audit-driven episode), nursing-labor inflation outrunning pricing, Roto-Rooter softness (quiet weather year, housing/recession drag), competitive intensity from private-equity-backed plumbing roll-ups, and a de-rating. The thesis depends on the VITAS pipeline (census growth + Medicare payment + hospice cap compliance + nursing-labor management + tuck-in M&A) plus the Roto-Rooter pipeline (residential plumbing demand + weather-driven water-restoration + brand strength + technician productivity + tuck-in M&A) plus the conservative balance sheet plus the heavy buyback program plus the growing dividend plus Kevin McNamara's continued stewardship of the decentralized two-business compounding model.